Hybridan Small Cap Feast - 9 April 2024

9th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Helix Exploration (HEX.L) a helium exploration company with operations in Montana, USA announces admission of its Ordinary Shares to trading on the AIM market of the London Stock Exchange. An Oversubscribed placing with book of demand over £22m to raise gross proceeds of

Morning Note – 9 April 2024

hVIVO - FY 2023 results, revenue in-line, margin better, future is bright

hVIVO has delivered FY 2023A results in-line with the 30 January 2024 TU, with total customer revenues of £56m, growth of 16% versus 2022A. Other income related to tax credits added another £2.6m. 2024 revenue guidance of £62m has been reiterated, representing 11% growth over 2023A, and ahead of the £60m that we had previously forecast. The company has good visibility with the 2024 figure, with 90% already being covered by the existing orderbook (stands at £80m at the end of 2023), as well as in

Hybridan Daily Feast - 30 Jan 24

30th January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje

Morning Note – 30 January 2024

hVIVO - FY 2024 guidance ahead of forecasts

On 13 December 2023, hVIVO released a statement that trading was ahead of expectations and today’s FY 2023 results and 2024 guidance should be taken well by the market. 2023E revenues are expected to increase by 15.5% to £56.0m (2022 £48.5m), with Other Income related to R&D tax credits adding a further £2.6m (£2.2m). Initial guidance for 2024 revenues of £62m compares to our forecast of £60m. A further update to 2023E for the EBITDA margin has been provided, with 22% now expected versus the at

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (

Morning Note – 2 January 2024

hVIVO - New year, new contract

hVIVO has announced the signing of a £6.3m contract with a biotechnology client that will utilise the hVIVO Human Rhinovirus Human Challenge Study Model. The study is planned to be performed in the company’s new facilities in Canary Wharf in H2 2024. Revenues will be recognised by hVIVO in FY24E and FY25E. By providing early human efficacy data, the study has the potential (assuming a positive outcome), to enhance the value of the client’s asset. We leave our forecasts unchanged and remain posit